Comparison between 200mg QD and 100mg BID oral celecoxib in the treatment of knee or hip osteoarthritis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zeng, Chao ^a   Wei, Jie ^b   Li, Hui ^a   Yang, Tuo ^a   Gao, Shu Guang ^a   Li, Yu Sheng ^a   Xiong, Yi Lin ^a   Xiao, Wen Feng ^a   Luo, Wei ^a   Yang, Tu Bao ^b   Lei, Guang Hua ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DRUG DOSAGE FORM;

DRUG DOSAGE FORM; FACTUAL DATABASE; GASTROINTESTINAL DISEASES; HUMAN; JOINT; META ANALYSIS; ODDS RATIO; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PHYSIOLOGY; PLACEBO EFFECT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; CELECOXIB; CYCLOOXYGENASE 2 INHIBITORS; DATABASES, FACTUAL; DOSAGE FORMS; GASTROINTESTINAL DISEASES; HUMANS; JOINTS; ODDS RATIO; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PLACEBO EFFECT; TREATMENT OUTCOME;

EID: 84930225150     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10593     Document Type: Article

References (61)

1. Dieppe, P. A. & Lohmander, L. S. Pathogenesis and management of pain in osteoarthritis. Lancet. 365, 965-973 (2005).
2. Lawrence, R. C. et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 41, 778-799 (1998).
3. McAlindon, T. E. et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage 22, 363-388 (2014).
4. Brown, G. A. AAOS clinical practice guideline: treatment of osteoarthritis of the knee: evidence-based guideline, 2nd edition. J. Am. Acad. Orthop. Surg. 21, 577-579 (2013).
5. Zarraga, I. G. E. & Schwarz, E. R. Coxibs and heart disease: what we have learned and what else we need to know. J. Am. Coll. Cardiol. 49, 1-14 (2007).
6. European Medicines Agency. EMEA public statement on the suspension of the marketing authorisation for Bextra (valdecoxib) in the European Union [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/Public- statement/2009/12/WC500018391.pdf (2005) Date of access: 10/09/2014
7. Gong, L. et al. Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics 22, 310-318 (2012).
8. Williams, G. W. et al. Treatment of osteoarthritis with a once-daily dosing regimen of celecoxib: a randomized, controlled trial. J. Clin. Rheumatol. 6, 65-74 (2000).
9. Williams, G. W., Hubbard, R. C., Yu, S. S., Zhao, W. & Geis, G. S. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clin. Ther. 23, 213-227 (2001).
10. Stengaard-Pedersen, K., Ekesbo, R., Karvonen, A. L. & Lyster, M. Celecoxib 200 mg q.d. is efficacious in the management of osteoarthritis of the knee or hip regardless of the time of dosing. Rheumatology (Oxford) 43, 592-595 (2004).
11. Davies, N. M., McLachlan, A. J., Day, R. O. & Williams, K. M. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin. Pharmacokinet. 38, 225-242 (2000).
12. Caldwell, D. M., Ades, A. E. & Higgins, J. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331, 897-900 (2005).
13. Caldwell, D. M., Welton, N. J. & Ades, A. E. Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency. J. Clin. Epidemiol. 63, 875-882 (2010).
14. Lumley, T. Network meta-analysis for indirect treatment comparisons. Stat. Med. 21, 2313-2324 (2002).
15. Lu, G. & Ades, A. E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat. Med. 23, 3105-3124 (2004).
16. Cipriani, A., Higgins, J. P., Geddes, J. R. & Salanti, G. Conceptual and technical challenges in network meta-analysis. Ann. Intern. Med. 159, 130-137 (2013).
17. Bucher, H. C., Guyatt, G. H., Griffith, L. E. & Walter, S. D. The results of direct and indirect treatment comparisons in metaanalysis of randomized controlled trials. J. Clin. Epidemiol. 50, 683-691 (1997).
18. Nüesch, E. et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 341, c3515 (2010).
19. Elia, N. & Tramer, M. R. Ketamine and postoperative pain-a quantitative systematic review of randomized trials. Pain 113, 61-70 (2005).
20. Jadad, A. R. et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin. Trials 17, 1-12 (1996).
21. Jüni, P., Reichenbach, S. & Dieppe, P. Osteoarthritis: rational approach to treating the individual. Best. Pract. Res. Clin. Rheumatol. 20, 721-740 (2006).
22. Zeng, C. et al. Effectiveness of continuous and pulsed ultrasound for the management of knee osteoarthritis: a systematic review and network meta-analysis. Osteoarthritis Cartilage 22, 1090-1099 (2014).
23. Zeng, C. et al. Electrical stimulation for pain relief in knee osteoarthritis: systematic review and network meta-analysis. Osteoarthritis Cartilage 23, 189-202 (2015).
24. Trelle, S. et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 342, c7086 (2011).
25. Wu, H. Y. et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and Bayesian network meta-analysis. BMJ 347, f6008 (2013).
26. Chaimani, A., Higgins, J. P., Mavridis, D., Spyridonos, P. & Salanti, G. Graphical tools for network meta-analysis in STATA. PLoS One 8, e76654 (2013).
27. Dias, S., Welton, N. J., Caldwell, D. M. & Ades, A. E. Checking consistency in mixed treatment comparison meta-analysis. Stat. Med. 29, 932-944 (2010).
28. Salanti, G., Ades, A. E. & Ioannidis, J. P. Graphical methods and numerical summaries for presenting results from multipletreatment meta-analysis: an overview and tutorial. J. Clin. Epidemiol. 64, 163-171 (2011).
29. Begg, C. B. & Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088-1101 (1994).
30. Bensen, W. G. et al. Treatment of osteoarthritits with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo. Clin. Proc. 74, 1095-1105 (1999).
31. Conaghan, P. G., Dickson, J., Bolten, W., Cevc, G. & Rother, M. A multicenter, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IEDA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis. Rheumatology (Oxford) 52, 1303-1312 (2013).
32. McKenna, F. et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J. Rheumatol. 30, 11-18 (2001).
33. Rother, M. et al. Efficacy and safety of epicutaneous ketoprefen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicenter randomised controlled trial. Ann. Rheum. Dis. 66, 1178-1183 (2007).
34. Zhao, S. Z. et al. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy 19, 1269-1278 (1999).
35. Bingham, C. O. 3rd, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford) 46, 496-507 (2007).
36. Clegg, D. O. et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N. Engl. J. Med. 23, 795-808 (2006).
37. DeLemos, B. P. et al. Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial. Am. J. Ther. 18, 216-226 (2011).
38. Fleischmann, R. et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib. Clin. Rheumatol. 25, 42-53 (2006).
39. Hochberg, M. C., Fort, J. G., Svensson, O., Hwang, C. & Sostek, M. Fixed-dose combination of enteric-coated naproxen and immediate-release escomeprazole has compoarable efficacy to celecoxib for knee osteoarthritis: two randomized trials. Curr. Med. Res. Opin. 27, 1243-1253 (2011).
40. Kivitz, A. J. et al. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J. Int. Med. Res. 29, 467-479 (2001).
41. Lehmann, R. et al. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib. Curr. Med. Res. Opin. 21, 517-526 (2005).
42. Lisse, J., Espinoza, L., Zhao, S. Z., Dedhiya, S. D. & Osterhaus, J. T. Functional status and health-related quality of life elderly osteoarthritic patients treated with celecoxib. J. Gerontol A Biol. Sci. Med. Sci. 56, M167-175 (2001).
43. Schnitzer, T. J. et al. A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis. Clin. Rheumatol. 30, 1433-1446 (2011).
44. Sheldon, E. et al. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo. Clin. Ther. 27, 64-77 (2005).
45. Smugar, S. S. et al. Rofecoxib 12.5 mg, rofecoxib 25 mg, and celecoxib 200 mg in the treatment of symptomatic osteoarthritis: results of two similarly designed studies. Curr. Med. Res. Opin. 22, 1353-1367 (2006).
46. Tannenbaum, H. et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Ann. Rheum. Dis. 63, 1419-1426 (2004).
47. Deeks, J. J., Smith, L. A. & Bradley, M. D. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 325, 619 (2002).
48. Essex, M. N., Zhang, R. Y., Berger, M. F., Upedhyay, S. & Park, P. W. Safety of celecoxib compared with placebo and non-selective NASIDs: cumulative meta-analysis of 89 randomized controlled trials. Expert Opin. Drug. Saf. 12, 465-477 (2013).
49. Moore, R. A., Derry, S., Makinson, G. T. & McQuay, H. J. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trials reports. Arthritis Res. Ther. 7, R644-665 (2005).
50. Kearney, P. M. et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of antherothrombosis? Meta-analysis of randomised trials. BMJ 332, 1302-1308 (2006).
51. White, W. B. et al. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials. Am. J. Cardio 99, 91-98 (2007).
52. McGettigan, P. & Henry, D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitions of cyclooxygenase 2. JAMA 296, 1633-1644 (2006).
53. Moore, A., Makinson, G. & Li, C. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51, 000 patients enrolled in 52 randomized trials. Arthritis Res. Ther. 15, R6 (2013).
54. Ashcroft, D. M., Chapman, S. R., Clark, W. K. & Millson, D. S. Upper gastroduodenal ulceration in arthritis patients treated with celecoxib. Ann Pharmacother 35, 829-834 (2001).
55. McCormack, P. L. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs 71, 2457-2489 (2011).
56. Solomon, S. D. et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 114, 1028-1035 (2006).
57. Antoniou, K., Malamas, M. & Drosos, A. A. Clinical pharmacology of celecoxib, a COX-2 selective inhibitor. Expert Opin. Pharmacother 8, 1719-1732 (2007).
58. Solomon, S. D. et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117, 2104-2113 (2008).
59. Paulson, S. K. et al. Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. Drug Metab. Dispos 28, 308-314 (2000).
60. Huelin, R., Pokora, T., Foster, T. S. & Mould, J. F. Economic outcomes for celecoxib: a systematic review of pharmacoeconomic studies. Expert Rev. Pharmacoecon Outcomes Res. 12, 505-523 (2012).
61. Wandel, S. et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network metaanalysis. BMJ 341, c4675 (2010).